TORL BioTherapeutics

TORL BioTherapeutics is a private, pre-revenue biotech advancing a pipeline of targeted antibody-drug conjugates for oncology, with its lead program, TORL-1-23, in Phase 2 development for CLDN6+ cancers. The company leverages a unique, scalable drug discovery engine born from a strategic partnership with the Slamon Research Lab at UCLA, enabling the identification of promising targets and patient selection biomarkers. Led by an experienced team with deep oncology drug development and commercialization expertise, including former Celgene CEO Mark Alles, TORL is positioned to advance its multi-asset pipeline through global clinical development.

Scalable drug discovery technology platform enabled by a unique, long-term partnership with the Slamon Research Lab at UCLA. The platform focuses on identifying novel tumor-associated antigens (like CLDN6, DLK1), developing targeted antibodies (primarily ADCs), and defining patient selection biomarkers for a precision medicine approach.

TORL competes in the crowded but growing antibody-drug conjugate (ADC) oncology market. Its key differentiation is targeting novel antigens (CLDN6, DLK1) with limited competition. However, it faces indirect competition from other targeted therapies and must demonstrate superior efficacy/safety. Several large pharma and biotech firms have major ADC platforms and could enter these target spaces.